Press Releases

First Previous Next End

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

October 15, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

Provectus announced today that Shari Pilon-Thomas, Ph.D. from the Moffitt Cancer Center will present the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting in two time slots on Saturday, November 8: 12:30 pm - 2:00 pm and 6:00 pm - 7:30 pm.

October 14, 2014

INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals

Provectus announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

October 8, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology

Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's Cancer Center will present data on its investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 7, 2014

Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress

Provectus announced today that clinical data on its investigative new drug PV-10 for the treatment of melanoma will be presented at the 2014 Beijing International Melanoma Congress. The presentation by Dr. Sanjiv Agarwala of the St. Luke's Cancer Center is titled "Current Perspectives on Intralesional Therapies." It is scheduled for 5:30 pm local time, on Saturday, October 18, 2014.

September 29, 2014

Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma was featured in a poster presentation on Sunday, September 28, 2014 during the European Society For Medical Oncology 2014 Congress in Madrid, Spain. The presentation showed that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

September 24, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at
https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.

September 23, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting with an abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma."

September 22, 2014

Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it has appointed Christopher Kaplan to its Strategic Advisory Board effective immediately.

August 18, 2014

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it entered into a Memorandum of Understanding ("MOU") with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

August 6, 2014

Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will begin a series of regular quarterly conference calls to update the market in general and shareholders in particular about developments at the Company. In the future, these calls will coincide with the filing of the Company's 10-Q and 10-K filings with the Securities and Exchange Commission as appropriate.

July 23, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will have clinical data on PV-10 presented at the European Society for Medical Oncology's 2014 Congress in Madrid, Spain.

July 8, 2014

Provectus Updates Shareholders in Its Annual CEO Letter

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2013, and shares as well as insights on upcoming plans and milestones for 2014.

June 19, 2014

Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.

June 12, 2014

Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

June 3, 2014

PV-10 Data Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Defines Path Forward for Provectus Biopharmaceuticals, Inc.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

May 27, 2014

Provectus Biopharmaceuticals Inc. to Hold Conference Call Tuesday, June 3, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Tuesday, June 3, 2014 at 8:30 a.m. EDT.

May 23, 2014

Provectus Biopharmaceuticals Inc. Reaffirms Its Commitment to Bringing PV-10 to Market Notwithstanding FDA Decision on Breakthrough Therapy Designation

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received notification from the United States Food and Drug Administration that the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies. As a result, the FDA has declined to designate PV-10 as a Breakthrough Therapy at this time. Further data may cause the Agency to revisit this decision at a later date. PV-10 is the Company's novel investigational drug for solid tumors.

First Previous Next End